Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01445028 · ClinicalTrials.gov registry record · Phase 4

Isotretinoin for Proliferative Vitreoretinopathy

A Phase 4 study, sponsored by Wills Eye.

Completed
Registry status
Phase 4
Development phase
109
Enrollment target

NCT01445028: Completed Phase 4 study, sponsored by Wills Eye.

NCT01445028 is a Phase 4 study that has completed, run by Wills Eye. The registered enrollment target is 109 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01445028, a Phase 4 study, has completed, sponsored by Wills Eye.

COMPLETED
Registry status
Phase 4
Development phase
109 participants
Enrollment target

Study Summary

Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.

Primary Outcome

We will evaluate all patients for retinal attachment at 3 months.

Interventions

  • DRUG Isotretinoin

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2011-09
Est. Completion 2015-08
Phase Phase 4
Wills Eye

59 total trials

What the finished NCT01445028 record still lists

NCT01445028 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 1 intervention - of which Isotretinoin is the first listed.

NCT01445028 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01445028 about?

NCT01445028 is a clinical study titled "Isotretinoin for Proliferative Vitreoretinopathy". Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), o...

What is the current status of trial NCT01445028?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 109 participants. The study started on 2011-09. Estimated completion is 2015-08.

What interventions are being tested in trial NCT01445028?

The interventions under investigation include: Isotretinoin (DRUG).

Who is sponsoring clinical trial NCT01445028?

This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01445028's enrollment target sits among peer trials

109 737th of 2000 higher than 1,261 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02421380 · 109 participants · NA

    Characterization of Hyperpolarized Pyruvate MRI Reproducibility

  • NCT04526600 · 109 participants · NA

    Fidgeting and Attentional and Emotional Regulation in ADHD

  • NCT04835584 · 109 participants · Phase 1

    KRT-232 and TKI Study in Chronic Myeloid Leukemia

  • NCT06626516 · 109 participants · Phase 1

    Tebentafusp-tebn With LDT in Metastatic UM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01445028, the US trial registry maintained by the National Library of Medicine. NCT01445028 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.